As New Entrants Prepare To Enter The Ulcerative Colitis Market, Which Agents Will Be Disadvantaged?

P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).